The originating document has been archived. We cannot confirm the completeness, accuracy and currency of the content.
Lidocaine Hydrochloride / Prilocaine
Pronunciation: LIE-doe-cane HIGH-droe-KLOR-ide/PRILL-oh-cane
Class: Local anesthetic, Topical
- Cream 2.5% lidocaine and 2.5% prilocaine
- Anesthetic Disc 1 g EMLA emulsion (2.5% lidocaine, 2.5% prilocaine). Contact surface approximately 10 cm 2
Stabilizes neuronal membranes by inhibiting the ionic fluxes required for the initiation and conduction of impulses, thereby effecting local anesthetic action.
Indications and Usage
As a topical anesthetic for use on normal intact skin for local analgesia or genital mucous membranes for superficial minor surgery and as pretreatment for infiltration anesthesia.
Sensitivity to local anesthetics of the amide type or any component of the product.
Dosage and AdministrationMinor Dermal Procedures
Topical Apply 2.5 g of cream over 20 to 25 cm 2 of skin surface or 1 anesthetic disc (1 g over 10 cm 2 ) for at least 1 h.Major Dermal Procedures
Topical Apply 2 g of the cream per 10 cm 2 of skin surface and allow to remain in contact with skin for at least 2 h.Male Genital Skin
Topical As adjunct prior to local anesthetic infiltration, apply a thick layer of cream (1 g/10 cm 2 ) to the skin surface for 15 min. Perform local anesthetic infiltration immediately after removal of the cream.Female Genital Mucous Membranes
Topical Apply a thick layer (5 to 10 g) of cream for 5 to 10 min.Pediatrics (Intact skin)
Children (0 to 3 mo or less than 5 kg)
Topical Apply 1 g per 10 cm 2 for a max of 1 h.Children (3 mo up to 12 mo and more than 5 kg)
Topical Apply 2 g per 20 cm 2 for a max of 4 h.Children (1 yr to 6 yr and more than 10 kg)
Topical Apply 10 g per 100 cm 2 for a max of 4 h.Children (7 yr to 12 yr and more than 20 kg)
Topical Apply 20 g per 200 cm 2 for a max of 4 h.Note
If a patient is older than 3 mo and does not meet the min weight requirement, the max total dose should be restricted to that which corresponds to the patient's weight.
- For topical use only. Not for ophthalmic or otic use.
- Dermal analgesia can be expected to increase for up to 3 h under occlusive dressing and persist for 1 to 2 h after removal of the cream.
Store at controlled room temperature (59° to 86°F). Keep tube tightly closed.
Drug InteractionsClass I antiarrhythmic agents (eg, mexiletine, tocainide)
Toxic effects may be additive or synergistic.Methemoglobin-inducing agents
May increase risk of methemoglobinemia.
Laboratory Test Interactions
None well documented.
Bradycardia; hypotension, CV collapse leading to arrest.
CNS excitement or depression; lightheadedness; nervousness; apprehension; euphoria; confusion; dizziness; drowsiness; sensations of hot, cold, or numbness; twitching; tremors; convulsions, unconsciousness; respiratory depression and arrest.
Paleness (37%); erythema (30%); burning sensation (17%); edema (10%); alterations in temperature sensations (7%); itching (2%); discrete purpuric or petechial reactions at the site of application; hyperpigmentation (cream); redness; blistering of foreskin in neonates about to undergo circumcision.
Tinnitus; blurred or double vision.
Allergic and anaphylactoid reactions (characterized by urticaria, angioedema, bronchospasm, and shock).
Category B .
Lidocaine and probably prilocaine are excreted in human milk.
Children under 7 yr have shown less overall benefit than older children or adults. Do not use in neonates with a gestational age of 37 wk or less.
Application to larger areas or for longer than recommended could result in sufficient absorption causing serious adverse reactions.
Do not use in patients with congenital or idiopathic methemoglobinemia or in infants under 12 mo of age who are receiving treatment with methemoglobin-inducing agents (eg, acetaminophen, nitrates, phenytoin, sulfonamides).
Confusion, drowsiness, unconsciousness, tremors, convulsions, hypotension, bradycardia, CV collapse, cardiac arrest, tinnitus, diplopia.
- Review the patient information leaflet, including instructions for administration, with patient, parent, or guardian.
- Review prescribed dosing schedule with patient, parent, or guardian.
- Caution parent or guardian to not exceed prescribed dose, area of application, nor duration of application when using in infants and young children.
- Caution patient, parent, or guardian that medication may block all skin sensations and to avoid trauma to the treated area by scratching, rubbing, or exposure to extreme hot or cold temperatures until complete sensation has returned.
- Caution patient, parent, or guardian not to apply near eyes or on open wounds.
- Advise patient, parent, or guardian to remove cream and contact health care provider immediately if any of the following occur following application of cream: dizziness; excessive sleepiness; bluish discoloration of face or lips; agitation; twitching; tremors; serious reaction at application site.
Copyright © 2009 Wolters Kluwer Health.